Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.
2.

Hematopoietic stem cell transplantation for HIV cure.

Kuritzkes DR.

J Clin Invest. 2016 Feb;126(2):432-7. doi: 10.1172/JCI80563. Epub 2016 Jan 5. Review.

PMID:
26731468
3.

Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.

Schackman BR, Haas DW, Park SS, Li XC, Freedberg KA.

Pharmacogenomics. 2015 Dec;16(18):2007-18. doi: 10.2217/pgs.15.142. Epub 2015 Nov 26.

4.

Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism.

Jeanne N, Saliou A, Carcenac R, Lefebvre C, Dubois M, Cazabat M, Nicot F, Loiseau C, Raymond S, Izopet J, Delobel P.

Sci Rep. 2015 Nov 20;5:16944. doi: 10.1038/srep16944.

5.

Maraviroc: a review of its use in HIV infection and beyond.

Woollard SM, Kanmogne GD.

Drug Des Devel Ther. 2015 Oct 1;9:5447-68. doi: 10.2147/DDDT.S90580. eCollection 2015. Review.

6.

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study.

Sierra-Madero JG, Ellenberg S, Rassool MS, Tierney A, Belaunzarán-Zamudio PF, López-Martínez A, Piñeirúa-Menéndez A, Montaner LJ, Azzoni L, Benítez CR, Sereti I, Andrade-Villanueva J, Mosqueda-Gómez JL, Rodriguez B, Sanne I, Lederman MM; CADIRIS study team.

Lancet HIV. 2014 Nov 1;1(2):e60-e67.

7.

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.

van Lelyveld SF, Drylewicz J, Krikke M, Veel EM, Otto SA, Richter C, Soetekouw R, Prins JM, Brinkman K, Mulder JW, Kroon F, Middel A, Symons J, Wensing AM, Nijhuis M, Borghans JA, Tesselaar K, Hoepelman AI; MIRS study group.

PLoS One. 2015 Jul 24;10(7):e0132430. doi: 10.1371/journal.pone.0132430. eCollection 2015.

8.

Maraviroc - A CCR5 Antagonist for the Treatment of HIV-1 Infection.

Van Der Ryst E.

Front Immunol. 2015 Jun 5;6:277. doi: 10.3389/fimmu.2015.00277. eCollection 2015. Review. No abstract available.

9.

A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops.

Lombardi F, Nakamura KJ, Chen T, Sobrera ER, Tobin NH, Aldrovandi GM.

PLoS One. 2015 Jun 17;10(6):e0128116. doi: 10.1371/journal.pone.0128116. eCollection 2015.

10.

Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.

Gombos RB, Kolodkin-Gal D, Eslamizar L, Owuor JO, Mazzola E, Gonzalez AM, Korioth-Schmitz B, Gelman RS, Montefiori DC, Haynes BF, Schmitz JE.

J Virol. 2015 Aug;89(15):7813-28. doi: 10.1128/JVI.00783-15. Epub 2015 May 20.

11.

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.

Sierra S, Dybowski JN, Pironti A, Heider D, Güney L, Thielen A, Reuter S, Esser S, Fätkenheuer G, Lengauer T, Hoffmann D, Pfister H, Jensen B, Kaiser R.

PLoS One. 2015 May 13;10(5):e0125502. doi: 10.1371/journal.pone.0125502. eCollection 2015.

12.
13.

Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Kryst J, Kawalec P, Pilc A.

PLoS One. 2015 May 1;10(5):e0124279. doi: 10.1371/journal.pone.0124279. eCollection 2015. Review.

14.

Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor Settings.

Duwal S, Winkelmann S, Schütte C, von Kleist M.

PLoS Comput Biol. 2015 Apr 30;11(4):e1004200. doi: 10.1371/journal.pcbi.1004200. eCollection 2015 Apr.

15.

Epidemiology and management of antiretroviral-associated cardiovascular disease.

Chastain DB, Henderson H, Stover KR.

Open AIDS J. 2015 Mar 31;9:23-37. doi: 10.2174/1874613601509010023. eCollection 2015.

16.

Clinical relevance of CYP3A5 genotype on maraviroc exposures.

Vourvahis M, McFadyen L, Heera J, Clark A.

Drug Metab Dispos. 2015 May;43(5):771-2. doi: 10.1124/dmd.115.063321. No abstract available.

17.

Reliable genotypic tropism tests for the major HIV-1 subtypes.

Cashin K, Gray LR, Harvey KL, Perez-Bercoff D, Lee GQ, Sterjovski J, Roche M, Demarest JF, Drummond F, Harrigan PR, Churchill MJ, Gorry PR.

Sci Rep. 2015 Feb 25;5:8543. doi: 10.1038/srep08543.

18.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ.

Pharmacogenet Genomics. 2015 Feb;25(2):51-9. doi: 10.1097/FPC.0000000000000106.

19.

Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.

Soulie C, Peytavin G, Charpentier C, Lambert-Niclot S, Sayon S, Visseaux B, Simon A, Katlama C, Yazdanpanah Y, Descamps D, Calvez V, Marcelin AG.

AIDS Res Hum Retroviruses. 2015 May;31(5):475-8. doi: 10.1089/AID.2014.0223. Epub 2014 Dec 17.

20.

Genotypic prediction of tropism of highly diverse HIV-1 strains from Cameroon.

Mbondji-Wonje C, Ragupathy V, Zhao J, Nanfack A, Lee S, Torimiro J, Nyambi P, Hewlett IK.

PLoS One. 2014 Nov 7;9(11):e112434. doi: 10.1371/journal.pone.0112434. eCollection 2014.

Items per page

Supplemental Content

Write to the Help Desk